Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b

    loading  Checking for direct PDF access through Ovid



Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-β) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy.


Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-β group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb.


A higher percentage of patients with RBV maintenance was observed in the EPO-β group compared with the untreated group (nadir Hb level <10.5 g/dL; 70% vs. 38%, P = 0.020; nadir Hb < 10 g/dL; 62% vs. 27%, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-β group when compared with the untreated group, especially for patients receiving a total EPO-β dose of more than 16 000 U (+0.70 g/dL vs. −0.32 g/dL, P = 0.023) and of 10 000 U-14 000 U (+0.60 g/dL vs. −0.32 g/dL, P = 0.023).


Low-dose EPO-β can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

Related Topics

    loading  Loading Related Articles